Pharma and Biotech Daily: Merck's $3 Billion Commitment and Industry Updates

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Merck has committed up to $3 billion in a deal with Lanova Medicines focused on PD-1/VEGF. The deal comes as Merck faces competition from Bristol Myers Squibb in leukemia, leading Allogene to end phase I enrollment. Analysts view Merck's move as conservative, despite recent excitement around PD-1/VEGF. In other news, GSK is making a case for Blenrep in multiple myel...